Dr. Jonathan David Greifenkamp, MD

Dr. Greifenkamp practices at Longview Regional Medical Center in Longview, Texas, part of Community Health Systems.

Dr. Greifenkamp's NPI, 1235333808, was assigned on June 14, 2007. Dr. Greifenkamp graduated from UTMB Health in 2000. Dr. Greifenkamp holds Texas license L6919.

Dr. Greifenkamp's primary practice is Longview Regional Medical Center, at 2901 N Fourth St, Longview, TX 75605 in Gregg County. The practice phone is (903) 758-1818.

Dr. Greifenkamp's primary practice is Longview Regional Medical Center in Longview, Texas, part of Community Health Systems. Dr. Greifenkamp is also affiliated with CHRISTUS Good Shepherd Medical Center - Longview. The medical group on file is Regional Clinics. Dmand AI also links Dr. Greifenkamp to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Greifenkamp practices, 4 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Greifenkamp's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Greifenkamp is board certified in cardiovascular disease by the National Board of Physicians and Surgeons. Dr. Greifenkamp is licensed in Texas.

Dmand AI lists aneurysm, angioplasty, arterial blot clot /embolism, atrial fibrillation and flutter, cardiac catheterization, cardiomyopathy, cerebrovascular disease and chronic embolism thrombosis among the conditions Dr. Greifenkamp treats.

CMS data shows 5,366 Medicare services from Dr. Greifenkamp across 43 procedure codes in 2024, for 1,459 Medicare patients. Medicare paid $499,310 for them.

CMS counts 1,459 Medicare patients who saw Dr. Greifenkamp in 2024. The largest group is 65 to 74, with 619 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Greifenkamp's median patient age at 74, with 48% women.

In 2024, Dr. Greifenkamp wrote 4,953 Medicare Part D claims for 809 patients. 81% of them were for generic drugs. CMS names the drug for 4,716 of them, across 46 drugs with 11 or more claims each, at $795,704 in total drug cost. In 2023, CMS named 5,135 claims across 46 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Greifenkamp for performance year 2024, reported through an alternative payment model (APM). Dr. Greifenkamp accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 81 procedures of coronary angioplasty and stenting by Dr. Greifenkamp, more than 94% of the clinicians it reports for that procedure.

Dmand AI links 1 paper to Dr. Greifenkamp in 2018. Dr. Greifenkamp's most frequent co-author is Samir V. Germanwala, DO.

CMS Open Payments shows 1,443 general payments to Dr. Greifenkamp from 55 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 93% of the total. Abbott Laboratories paid the most, $4,106.

Dmand AI lists 3 awards for Dr. Greifenkamp, most recently ACC Fellow in 2011.

Dr. Greifenkamp graduated from UTMB Health in 2000. Dr. Greifenkamp is a member of ACC and SCAI.

Dr. Greifenkamp is in network with 22 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.